Tirzepatide Overview
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection, FDA-approved for type 2 diabetes (2022) and obesity (2023), with dosing starting at 2.5 mg weekly and titrating monthly to a maximum of 15 mg weekly. 1
What is Tirzepatide?
Tirzepatide is a synthetic 39-amino acid peptide engineered from the native glucose-dependent insulinotropic polypeptide (GIP) sequence that acts on both GIP and GLP-1 receptors. It represents a second-generation obesity medication and works centrally to impact weight, while also increasing insulin secretion, reducing glucagon release in a glucose-dependent manner, promoting satiety, and delaying gastric emptying. 1, 2
The medication has a half-life of 116.7 hours, allowing for once-weekly administration. 1
FDA-Approved Indications
Tirzepatide is approved at doses of 5,10, and 15 mg weekly for:
- Type 2 diabetes mellitus (as adjunct to diet and exercise) - approved 2022 1
- Obesity management - approved 2023 1
- Moderate-to-severe obstructive sleep apnea in adults with obesity - approved December 2024 1
Dosing Schedule
Start at 2.5 mg subcutaneously once weekly, then titrate up monthly:
- Week 1-4: 2.5 mg weekly
- Week 5-8: 5 mg weekly (maintenance dose option)
- Week 9-12: 10 mg weekly (maintenance dose option)
- Week 13+: 15 mg weekly (maximum dose)
The injection can be administered at any time of day, with or without meals. If a dose is missed, administer as soon as possible within 4 days; if more than 4 days have passed, skip the missed dose. 3
Critical dosing principle: Slow monthly titration is essential to minimize gastrointestinal side effects. If treatment is discontinued or paused for an extended period, restart at the lowest dose (2.5 mg) and re-titrate to allow the body to acclimate. 1
Clinical Efficacy
In Type 2 Diabetes (SURPASS Trials)
- HbA1c reduction: 1.9% to 2.0%, with >87% of patients reaching HbA1c target <7% 1
- Weight loss: 12.8% (10 mg dose) to 14.7% (15 mg dose) in patients with type 2 diabetes 1
- Nearly half of participants achieved normal HbA1c values (<5.7%) with minimal hypoglycemia 1
In Obesity (SURMOUNT Trials)
- Weight reduction: Up to 22.5% at 72 weeks with 15 mg dose 1
- Nearly 40% of participants lost ≥25% of body weight 1
- Long-term treatment (88 weeks) resulted in weight reduction up to 26.6% 1
Important nuance: Weight loss efficacy is dampened in patients with type 2 diabetes compared to those with obesity alone, though still clinically significant. 1
Cardiovascular and Metabolic Benefits
- Does not increase MACE risk in type 2 diabetes patients (SURPASS-CVOT ongoing) 1
- Prevents progression from prediabetes to type 2 diabetes 1
- Improves heart failure with preserved ejection fraction (HFpEF) 1
- Ameliorates metabolic dysfunction-associated steatohepatitis (MASH) histology and fibrosis 1
- Reduces blood pressure and improves lipid parameters 4
Contraindications
Absolute contraindications (similar to GLP-1 receptor agonists): 5
- Personal or family history of medullary thyroid cancer
- Personal or family history of multiple endocrine neoplasia type 2 (MEN2)
- History of serious hypersensitivity reaction to tirzepatide
- Pregnancy or breastfeeding
Common Adverse Effects
Gastrointestinal effects (most common, occurring primarily during dose escalation): 1, 6
- Nausea (up to 25% of patients)
- Vomiting (up to 10%)
- Diarrhea (up to 10%)
- Constipation
- Abdominal discomfort
Other adverse effects:
- Modest increase in heart rate 1
- Injection site reactions 5
- Increased risk of gallbladder or biliary disease (applies to all GLP-1 receptor agonists) 1, 6, 1
- Elevations in lipase and amylase without pancreatitis 1
- Dehydration and renal impairment (in patients with vomiting/diarrhea) 1
Hypoglycemia risk: Low when used alone or with metformin; increased when combined with insulin, sulfonylureas, or glinides. 1, 7
Important Precautions and Monitoring
Pancreatitis
Discontinue immediately if pancreatitis is suspected; do not restart if confirmed. While insufficient data exist for causality, stop medication if severe abdominal pain with or without nausea/vomiting occurs. 5, 6
Gastroparesis
Not recommended in patients with clinically meaningful gastroparesis. Exercise caution in patients with prior gastric surgery, including bariatric surgery. 5
Renal Function
- No dosage adjustment required for renal impairment 8
- Monitor for dehydration and renal impairment in patients with vomiting or diarrhea 1
Diabetic Retinopathy
Monitor for diabetic retinopathy complications, though unclear if this is a direct drug effect or related to rapid glucose improvement. 5
Mood Changes
FDA recommends monitoring for mood changes, emerging or worsening depression, or suicidal behavior, though evidence is insufficient to support a causal association. 1
Strategies to Mitigate Side Effects
Essential counseling points for patients: 1, 6
- Start with the lowest dose (2.5 mg) and titrate slowly
- Eat smaller, more frequent meals rather than large portions
- Stop eating when feeling full (do not eat past fullness)
- Avoid fatty or spicy foods that may exacerbate symptoms
- Drink plenty of water
- Increase dietary fiber intake
- Eat slowly
- Moderate alcohol and fizzy drink intake
- Monitor which specific foods worsen symptoms
If treatment is interrupted: Restart at 2.5 mg and re-titrate to allow body acclimation. 1
Clinical Positioning
Tirzepatide should be considered as a preferred option for: 6, 9
- Adults with type 2 diabetes and obesity (BMI >30 kg/m² or BMI >27 kg/m² with weight-related comorbidity)
- Patients requiring both glycemic control and significant weight loss
- Patients with type 2 diabetes who have not achieved goals with other agents
Tirzepatide demonstrates superior efficacy compared to:
- Semaglutide 1.0 mg for both HbA1c reduction and weight loss 1, 10
- Titrated basal insulin 10
- Other GLP-1 receptor agonists 6, 9
The medication represents the most effective single agent currently available for combined glycemic control and weight reduction in type 2 diabetes. 9, 10, 11